Glycosaminoglycans regulate elastase inhibition by oxidized secretory leukoprotease inhibitor

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 272, Issue 3 16-3, 1997, Pages

  Ying, Qi Long ^b   Kemme, Michael ^b   Saunders, Derek ^b   Simon, Sanford R ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b NONE

Author keywords

dermatan sulfate; heparan sulfate; heparin; inflammation; oxidation of elastase inhibitors

Indexed keywords

CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; LEUKOCYTE ELASTASE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; ENZYME INHIBITOR COMPLEX; KINETICS; LEUKOCYTE; OXIDATION; PRIORITY JOURNAL; PROTEINASE INHIBITION; RESPIRATORY TRACT INFLAMMATION;

EID: 0030910018     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.1997.272.3.l533     Document Type: Article

References (35)

1. Boudier, C., and J. G. Bieth. Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitor. Biochem. J. 303: 61-68, 1994.
2. Bourin, M.-C., and U. Lindahl. Glycosaminoglycans and the regulation of blood coagulation. Biochem. J. 289: 313-330, 1993.
3. Carp, H., and A. Janoff. Inactivation of bronchial mucous proteinase inhibitor by cigarette smoke and phagocyte-derived oxidants. Exp. Lung Res. 1: 225-237, 1980.
4. Casu, B., M. Petitou, M. Provasoli, and P. Sinaÿ. Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem. Sci. 13: 221-225, 1988.
5. Domigan, N. M., T. S. Charlton, M. W. Duncan, C. C. Winterbourn, and A. J. Kettle. Chlorination of tyrosyl residues in peptides by myeloperoxidase and human neutrophils. J. Biol. Chem. 270: 16542-16548, 1995.
6. Edelhoch, H. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6: 1948-1954, 1967.
7. Eisenberg, S. P., K. K. Hale, P. Heimdal, and R. C. Thompson. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J. Biol. Chem. 265: 7976-7981, 1990.
8. Faller, B., Y. Mely, D. Gerard, and J. G. Bieth. Heparin-induced conformational change and activation of mucus proteinase inhibitor. Biochemistry 31: 8285-8290, 1992.
9. Fritz, H. Human mucus proteinase inhibitor (human MPI). Biol. Chem. Hoppe-Seyler Suppl. 369: 79-82, 1988.
10. 1-proteinase inhibitor. J. Biol. Chem. 266: 15356-15362, 1991.
11. Griffith, M. J. Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin. J. Biol Chem. 257: 7360-7365, 1982.
12. Grütter, M. G., G. Fendrich, R. Huber, and W. Bode. The 2.5 Å X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine α-chymotrypsin. EMBO J. 7: 345-351, 1988.
13. Han, J. C., and G. Y. Han. A procedure for quantitative determination of tris(2-carboxyethyl) phosphine, an odorless reducing agent more stable and effective than dithiothreitol. Anal. Biochem. 220: 5-10, 1994.
14. Heinzel-Wieland, R., G. J. Steffens, and L. Flohé. Inhibitory characteristics and oxidant resistance of site specific variants of recombinant human antileukoproteinase (ALP). Biomed. Biochim. Acta 50: 677-681, 1991.
15. Jackson, R. L., S. J. Busch, and A. D. Cardin. Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol. Rev. 71: 481-539, 1991.
16. Jacoby, A. S., J. Melrose, B. G. Robinson, V. J. Hyland, and P. Ghosh. Secretory leucocyte proteinase inhibitor is produced by human articular cartilage chondrocytes and intervertebral disc fibrochondrocytes. Eur. J. Biochem. 218: 951-957, 1993.
17. Janoff, A. Elastase in tissue injury. Annu. Rev. Med. 36: 207-216, 1985.
18. Kjellén, L., and U. Lindahl. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60: 443-475, 1991.
19. Kramps, J. A., C. van Twisk, E. C. Klasen, and J. H. Dijkman. Interaction among stimulated human polymorphonuclear leucocytes, released elastase and bronchial antileucoprotease. Clin. Sci. Lond. 75: 53-62, 1988.
20. Maier, K. L., A.-G. Lenz, I. Beck-Speier, and U. Costable. Analysis of methionine sulfoxide in proteins. Methods Enzymol. 251: 455-461, 1995.
21. McElvaney, N. G., B. Doujaiji, M. J. Moan, M. R. Burnham, M. C. Wu, and R. G. Crystal. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am. Rev. Respir. Dis. 148: 1056-1060, 1993.
22. Mellt, P., J. Ermolieff, and J. G. Bieth. Mapping the heparin-binding site of mucus proteinase inhibitor. Biochemistry 34: 2645-2652, 1995.
23. Morris, J. C. The acid ionization constant of HOCl from 5 to 35°. J. Phys. Chem. 70: 3798-3805, 1966.
24. Piccioni, P. D., J. A. Kramps, A. Rudolphus, A. Bulgheroni, and M. Luisetti. Proteinase/proteinase inhibitor imbalance in sputum sol phases from patients with chronic obstructive pulmonary disease. Suggestion for a key role played by antileukoprotease. Chest 102: 1470-1476, 1992.
25. Smith, C. E., M. S. Stack, and D. A. Johnson. Ozone effects on inhibitors of human neutrophil proteinases. Arch. Biochem. Biophys. 253: 146-155, 1987.
26. Test, S. T., M. B. Lampert, P. J. Ossanna, J. G. Thoene, and S. J. Weiss. Generation of nitrogen-chlorine oxidants by human phagocytes. J. Clin. Invest. 74: 1341-1349, 1984.
27. Tomova, S., F. Cutruzzolà, D. Barra, G. Amiconi, P. Ascenzi, K. D. Carugo, E. Menegatti, P. Sarti, H. P. Schnebli., and M. Bolognesi. Selective oxidation of methionyl residues in the human recombinant secretory leukocyte proteinase inhibitor. Effect on the inhibitor binding properties. J. Mol. Recognition 7: 31-37, 1994.
28. Vogelmeier, C., R. C. Hubbard, G. A. Fells, H.-P. Schnebli, R. C. Thompson, H. Fritz, and R. G. Crystal. Anti-neutrophil elastase defense of the normal respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J. Clin. Invest. 87: 482-488, 1991.
29. Weiss, S. J., R. Klein, A. Slivka, and M. Wei. Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation. J. Clin. Invest. 70: 598-607, 1982.
30. Wiedow, O., J. A. Young, M. D. Davison, and E. Christophers. Antileukoprotease in psoriatic scales. J. Invest. Dermatol. 101: 305-309, 1993.
31. Witko-Sarsat, V., C. Delacourt, D. Rabier, J. Bardet, A. T. Nguyen, and B. Descamps-Latscha. Neutrophil-derived long-lived oxidants in cystic fibrosis sputum. Am. J. Respir. Crit. Care Med. 152: 1910-1916, 1995.
32. Ying, Q.-L., M. Kemme, and S. R. Simon. Functions of the N-terminal domain of secretory leukoprotease inhibitor. Biochemistry 33: 5445-5450, 1994.
33. 1-proteinase inhibitor and accelerates inhibition by secretory leukoprotease inhibitor. Am. J. Respir. Cell Mol. Biol. 15: 283-291, 1996.
34. Ying, Q.-L., and S. R. Simon. Accelerated binding of secretory leukoprotease inhibitor to human leukocyte elastase mediated by single stranded sites in DNA from tracheobronchial mucus. Am. J. Respir. Cell Mol. Biol. 13: 703-711, 1995.
35. Zgliczynski, J. M., E. Olszowska, S. Olszowski, T. Stelmaszynska, and E. Kwasnowska. Apossible origin of chemiluminescence in phagocytosing neutrophils. Myeloperoxidase-mediated chlorination of proteins and tryptophan. Int. J. Biochem. 17: 393-397, 1985.